Skip to main content

AstraZeneca Confirms Updated Share Capital and Voting Rights

Tipranks - Tipranks - Tue Feb 3, 9:38AM CST

Claim 50% Off TipRanks Premium

AstraZeneca ( (GB:AZN) ) just unveiled an update.

AstraZeneca has confirmed that, as of 31 January 2026, its issued share capital with voting rights stands at 1,550,944,612 ordinary shares, with no shares held in treasury, resulting in a total of 1,550,944,612 voting rights in the company. This updated capital and voting rights figure, published in line with UK Financial Conduct Authority disclosure rules, provides investors with the key denominator needed to assess and report any changes in their shareholdings, reinforcing transparency and regulatory compliance in the company’s shareholder base.

More about AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company based in Cambridge, UK, focused on the discovery, development and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with products sold in more than 125 countries and used by millions of patients worldwide.

For an in-depth examination of AZN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).